Maternal hormonal homeostasis during gestation is critical to maintaining a healthy pregnancy and ensuring proper development of the fetus \[[@B1]\]. Human studies have shown that abnormal thyroid hormone levels, including hyperthyroidism and hypothyroidism, are associated with preterm birth \[[@B4]\] and low birth weight \[[@B11]\]. CRH is thought to play a major role in the timing of labor and has been shown to be associated with preterm birth in human studies \[[@B14]\]. Women with hyperandrogenic conditions such as polycystic ovarian syndrome have higher circulating levels of testosterone, and these types of conditions have been shown to be associated with preterm birth \[[@B21]\]. Additionally, elevated testosterone levels are associated with *in utero* growth restriction, development of gestational diabetes, and preeclampsia \[[@B22]\].

Phthalates are a class of synthetic plasticizers commonly found in consumer products that have been shown to be associated with numerous human health effects \[[@B26], [@B27]\]. Because phthalates are not chemically bound to the products in which they are used, they commonly leach into foods and beverages, dust, and air, creating multiple routes of potential human exposure \[[@B28]\]. Consequently, phthalates are ubiquitous in the environment and can be widely detected in humans, specifically pregnant women \[[@B29]\]. Because pregnant women represent a uniquely susceptible population, it is important to understand the potential effects of phthalate exposures on maternal and fetal physiology during pregnancy.

Animal studies have shown phthalate exposure to be associated with altered concentrations of serum reproductive \[[@B34]\] and thyroid hormones \[[@B38], [@B39]\] and reduced fertility \[[@B40]\]. Numerous human pregnancy studies have suggested that phthalates may play integral roles in determining birth weight, birth length, head circumference, gestational age, and risk of spontaneous abortion and preterm birth \[[@B33], [@B43]\]. Because of the growing body of evidence suggesting adverse effects of phthalate exposure on hormonal homeostasis and birth outcomes, we aimed to assess the relationships of maternal urinary phthalate and phthalate replacement metabolites with serum hormone concentrations over two time points during pregnancy in the Puerto Rico Testsite for Exploring Contamination Threats (PROTECT), our ongoing pregnancy cohort in Puerto Rico. Phthalate replacement chemical metabolites can be widely detected in urine among the United States population and may be increasing \[[@B53]\], yet few previous epidemiology studies have considered them. Additionally, to our knowledge no epidemiology studies have assessed the relationship between phthalate exposure and serum CRH concentrations, broadening the novelty and importance of the current study.

1. Methods {#s9}
==========

A. Study Participants {#s10}
---------------------

The present analysis builds upon a previous pilot study \[[@B54]\] and includes more participants and broader coverage of phthalate metabolites and hormone biomarkers, notably terephthalate metabolites and CRH. Participants were part of the PROTECT ongoing prospective birth cohort. Details on the study recruitment protocol are described elsewhere \[[@B32], [@B55]\]. Briefly, pregnant women living in the northern karst region of Puerto Rico were recruited from 2012 to 2017 from seven hospitals and prenatal clinics at 14 ± 2 weeks' gestation. Eligible participants were 18 to 40 years old, had their first clinic visit before 20 weeks' gestation, did not use oral contraceptives within 3 months of getting pregnant, did not use *in vitro* fertilization to get pregnant, and did not have any known medical or obstetric conditions. Participating women provided blood and spot urine samples for analysis at two time points during pregnancy coinciding with periods of rapid fetal growth: 16 to 20 weeks' and 24 to 28 weeks' gestation. Demographics information was collected from all participants at the first study visit. The present analysis included 677 women who had complete data on at least one phthalate/hormone concentration pair for at least one of the two study visits. This study was approved by the research and ethics committees of the University of Michigan School of Public Health, the University of Puerto Rico, Northeastern University, and participating hospitals and clinics. All study participants provided full informed consent prior to participation.

B. Urinary Phthalate Measurement {#s11}
--------------------------------

All spot urine samples were frozen at −80°C and shipped overnight on dry ice to the Centers for Disease Control and Prevention for analysis. All samples were initially analyzed for 15 phthalate metabolites: mono-2-ethylhexyl phthalate (MEHP), mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP), mono-2-ethyl-5-oxohexyl phthalate (MEOHP), mono-2-ethyl-5-carboxypentyl phthalate (MECPP), monoethyl phthalate (MEP), mono-*n*-butyl phthalate (MBP), monobenzyl phthalate (MBzP), monoisobutyl phthalate (MiBP), monohydroxyisobutyl phthalate (MHiBP), mono-3-carboxypropyl phthalate (MCPP), mono carboxyisononyl phthalate (MCNP), mono carboxyisooctyl phthalate (MCOP), mono hydroxybutyl phthalate (MHBP), mono isononyl phthalate (MNP), and mono oxononyl phthalate (MONP). Four additional phthalate replacement metabolites were later added to the analytical panel: cyclohexane-1,2-dicarboxylic acid monohydroxy isononyl ester (MHiNCH), cyclohexane-1,2-dicarboxylic acid monocarboxy isooctyl ester (MCOCH), mono-2-ethyl-5-carboxypentyl terephthalate (MECPTP), and mono-2-ethyl-5-hydrohexyl terephthalate (MEHHTP). Urine samples were analyzed using solid-phase extraction HPLC--isotope dilution tandem mass spectrometry, the details of which are described elsewhere \[[@B56]\]. Values detected below the limit of detection (LOD) were assigned a value of the LOD divided by the square root of two \[[@B57]\]. Differences in urinary dilution between samples were accounted for using specific gravity, which was measured using a digital handheld refractometer (Atago, Tokyo, Japan). Specific gravity correction for all urinary biomarkers was carried out using the formula *P*~c~ = *P*\[(*SG*~m~ − 1)/(*SG*~i~ − 1)\], where *P*~c~ is the specific gravity--corrected biomarker concentration (ng/mL), *P* is the measured biomarker concentration, *SG*~m~ is the median specific gravity value of the study population (1.019), and *SG*~i~ is the specific gravity value for each individual \[[@B33]\].

C. Serum Hormone Measurement {#s12}
----------------------------

All serum samples collected were analyzed at the Central Ligand Assay Satellite Services laboratory in the department of Epidemiology at the University of Michigan School of Public Health. Progesterone (Siemens, catalog no. 1586287) \[[@B58]\], SHBG (Siemens, catalog no. 6520781) \[[@B59]\], testosterone (Siemens, catalog no. 5476206) \[[@B60]\], total T3 (Siemens, catalog no. 8427516) \[[@B61]\], total T4 (Siemens, catalog no. 9236439) \[[@B62]\], free T4 (fT4; Siemens, catalog no. 6490106) \[[@B63]\], and TSH (Siemens, catalog no. 8700387) \[[@B64]\] were measured using a chemiluminescence immunoassay. Estriol (E3; DiaMetra, catalog no. DKO019) \[[@B65]\] and CRH (LifeSpan, catalog no. LS-F5352) \[[@B66]\] were measured using an enzyme immunoassay. Some hormone concentrations were not available for all participants due to volume limitations. The progesterone/E3 and T3/T4 ratios were assessed in addition to measured hormones. Previous research has indicated that these ratios may be a better indication of adverse pregnancy outcomes than single hormone measurements \[[@B67]\]. Two samples had TSH values of 0 and were thus dropped from the analysis owing to biological implausibility. Five samples had testosterone levels below the LOD and were thus replaced by the LOD divided by the square root of two.

D. Statistical Analyses {#s13}
-----------------------

Summary demographic characteristics of the population over the entire study period and at each visit were assessed including maternal age, maternal education, current job status, marital status, number of children, smoking status, environmental tobacco smoke exposure, alcohol use, number of previous pregnancies, and maternal prepregnancy BMI.

Distributions of all phthalate metabolites were heavily right skewed and thus were natural log transformed for all analyses. Distributions of CRH, E3, progesterone, TSH, and testosterone were also right skewed and natural log transformed for all analyses. Distributions of SHBG, fT4, T3, and T4 were approximately normal and thus were not transformed. Descriptive statistics for all phthalate metabolite and hormone distributions were calculated using specific gravity--adjusted values for all urinary biomarkers among the total study sample and for each study visit. Significant differences in concentrations of biomarkers between study visits were assessed using paired *t* tests with natural log transformation to achieve normality where appropriate.

Relationships between exposure and outcome variables and potential confounders were assessed using ANOVA to test for differences between categories of covariates, and then using linear regression to test for linear trends across categories of covariates. Final repeated measures analysis used linear mixed models to regress hormones/hormone ratios on phthalate metabolites and included random intercepts for each study participant to account for intraindividual correlation of exposure and outcome measures. Significance level of the univariate relationship between exposures and outcomes, *a priori* knowledge, and changes in the main effect estimate by at least 10% were criteria used when determining which potential covariates to include in final models. In addition to specific gravity, maternal age and maternal education were selected as covariates to include in final models. Estimates of *β* for categories of maternal age did not change linearly in final models, and thus maternal age was treated as a categorical variable for all analyses. Conversely, *β* estimates for categories of maternal education did change linearly, and thus maternal education was treated as an ordinal variable for subsequent analyses. To investigate potential windows of susceptibility, additional analyses were run that added an interaction term between study visit number and urinary phthalate biomarkers to the previously described linear mixed model to obtain effects estimates specific to each study visit.

For ease of interpretability, all results were transformed to indicate percent changes (%*Δ*) and 95% CIs in hormone concentrations associated with an interquartile range (IQR) increase in urinary phthalate metabolite concentration. We calculated *q* values using the Benjamini and Hochberg method \[[@B70]\] to address the issue of potential false-positive results from running many statistical tests. Each hormone biomarker was treated as a family of tests (total of 16 tests with phthalate metabolite biomarkers per hormone). High *q* values were seen as having a greater risk of being false-positives, whereas *q* values \<0.1 were interpreted with higher confidence. An *α* level of 0.05 was used to indicate statistical significance. All statistical analyses were run using R version 3.4.4.

2. Results {#s14}
==========

A. Demographics and Confounders {#s15}
-------------------------------

A total of 677 pregnant women were included in the present analysis. Of those, 405 and 272 women at visits 1 and 3, respectively, contributed blood and urine samples. Most women were \<30 years of age (72.3%), married (54.5%), nonsmokers (83.6%), nondrinkers (51.6%), had a BMI \<30 (82.1%), did not have any children (45.7%), and reported no exposure to environmental tobacco smoke (88.7%). Distributions of education level and employment status were relatively even between categories. Distributions of all demographic characteristics stratified by study visit were similar.

Distributions, geometric means and geometric SDs of all urinary phthalate metabolite and serum hormone biomarkers are shown in [Table 1](#tbl1){ref-type="table"}. All hormones except testosterone (N = 5 below LOD) were detected in 100% of included samples. Concentrations of E3, SHBG, progesterone, and testosterone were all significantly higher at visit 3 than at visit 1 (*P* \< 0.001). Most phthalate metabolite biomarkers were detected in at least 80% of samples. MCOCH, MNP, and MHiNCH were detected in \<35% of samples and were thus dropped from further analyses. Biomarker concentrations of all phthalate metabolites did not differ significantly between study visits.

###### 

Distributions of Hormones and Phthalate Metabolites in the Overall Study Population and at Visits 1 and 3

                                                                N     \% \>LOD   Min.   25th   50th   75th   90th   95th   Max.     GM     GSD    *P* Value[*^a^*](#tblfn1){ref-type="table-fn"}
  --------------------------------------------------- --------- ----- ---------- ------ ------ ------ ------ ------ ------ -------- ------ ------ ------------------------------------------------
  CRH[*^b^*](#tblfn2){ref-type="table-fn"}            Total     673   100        7.20   56.0   83.6   114    158    176    254      79.4   1.71   0.617
                                                      Visit 1   401   100        16.6   55.5   82.4   114    155    174    254      78.9   1.69   
                                                      Visit 3   272   100        7.20   56.8   86.6   114    159    179    249      80.3   1.73   
  E3[*^c^*](#tblfn3){ref-type="table-fn"}             Total     673   100        3.49   15.5   27.1   43.6   60.2   72.6   265      26.4   1.98   **0.000**
                                                      Visit 1   401   100        3.49   13.0   17.5   26.9   37.7   46.6   92.0     18.4   1.75   
                                                      Visit 3   272   100        11.1   33.7   44.6   57.7   73.1   97.2   265      44.7   1.60   
  SHBG[*^d^*](#tblfn4){ref-type="table-fn"}           Total     673   100        47.6   504    623    763    908    989    1502     612    1.40   **0.000**
                                                      Visit 1   401   100        47.6   484    589    713    854    937    1502     579    1.41   
                                                      Visit 3   272   100        279    523    673    831    976    1087   1381     665    1.36   
  Progesterone[*^c^*](#tblfn3){ref-type="table-fn"}   Total     673   100        17.4   44.3   61.6   88.4   134    158    1037     64.9   1.73   **0.000**
                                                      Visit 1   401   100        17.4   37.3   48.7   62.4   80.3   95.6   283      49.6   1.49   
                                                      Visit 3   272   100        28.1   71.7   90.4   128    164    235    1037     96.4   1.65   
  TSH[*^e^*](#tblfn5){ref-type="table-fn"}            Total     665   100        0.02   1.00   1.40   2.02   2.77   3.43   10.2     1.34   2.03   0.640
                                                      Visit 1   395   100        0.02   0.91   1.38   2.02   2.78   3.28   10.2     1.27   2.20   
                                                      Visit 3   270   100        0.14   1.10   1.48   2.00   2.73   3.56   5.47     1.46   1.75   
  fT4[*^f^*](#tblfn6){ref-type="table-fn"}            Total     673   100        0.71   1.00   1.08   1.18   1.26   1.32   1.72     1.08   1.13   **0.002**
                                                      Visit 1   401   100        0.71   1.02   1.10   1.19   1.27   1.35   1.72     1.10   1.14   
                                                      Visit 3   272   100        0.73   0.97   1.06   1.15   1.23   1.29   1.42     1.06   1.13   
  T3[*^c^*](#tblfn3){ref-type="table-fn"}             Total     671   100        1.04   1.71   1.98   2.22   2.46   2.59   3.16     1.94   1.21   0.292
                                                      Visit 1   400   100        1.04   1.70   1.97   2.22   2.44   2.56   3.16     1.93   1.21   
                                                      Visit 3   271   100        1.04   1.71   1.99   2.22   2.47   2.60   3.15     1.95   1.21   
  T4[*^g^*](#tblfn7){ref-type="table-fn"}             Total     672   100        6.80   10.5   11.8   13.3   14.6   15.5   19.0     11.7   1.19   0.261
                                                      Visit 1   400   100        6.80   10.6   11.9   13.3   14.7   15.5   19.0     11.8   1.19   
                                                      Visit 3   272   100        7.20   10.4   11.7   13.2   14.4   15.3   18.6     11.6   1.19   
  T[*^f^*](#tblfn6){ref-type="table-fn"}              Total     669   99         2.80   39.6   55.5   78.8   105    126    418      55.1   1.72   **0.001**
                                                      Visit 1   398   99         2.80   37.8   52.1   75.1   98.1   123    185      51.9   1.70   
                                                      Visit 3   271   99         9.20   45.1   61.4   87.0   111    129    418      60.2   1.71   
  mBP                                                 Total     674   99         0.44   9.35   17.5   32.3   60.3   81.0   297      16.9   2.72   0.931
                                                      Visit 1   404   99         0.44   9.54   17.7   30.6   61.1   81.4   297      17.1   2.73   
                                                      Visit 3   270   99         0.75   9.14   17.4   33.2   58.5   76.0   244      16.6   2.71   
  mBzP                                                Total     669   95         0.21   1.52   3.20   6.88   13.9   23.7   471      3.36   3.21   0.279
                                                      Visit 1   401   96         0.28   1.64   3.60   7.52   15.9   24.8   471      3.66   3.26   
                                                      Visit 3   268   93         0.21   1.43   2.70   6.05   11.2   20.5   114      2.97   3.11   
  mCNP                                                Total     665   99         0.26   1.26   1.91   3.07   6.05   8.79   172      2.14   2.25   0.760
                                                      Visit 1   396   99         0.50   1.33   2.00   3.19   6.22   10.3   71.0     2.21   2.25   
                                                      Visit 3   269   99         0.26   1.20   1.80   2.90   5.49   8.14   172      2.02   2.24   
  mCOP                                                Total     666   100        0.96   5.87   10.5   21.2   53.7   101    902      12.6   2.97   0.496
                                                      Visit 1   398   100        1.50   6.61   11.9   24.3   59.5   138    902      13.9   3.03   
                                                      Visit 3   268   100        0.96   5.09   10.0   17.3   47.1   73.4   609      10.8   2.83   
  mCPP                                                Total     668   88         0.14   0.87   1.60   2.94   6.44   10.2   168      1.75   2.76   0.513
                                                      Visit 1   398   90         0.14   0.93   1.69   3.16   6.91   10.8   83.6     1.84   2.72   
                                                      Visit 3   270   84         0.23   0.83   1.50   2.72   5.25   7.70   168      1.63   2.82   
  mECPP                                               Total     671   100        1.87   9.64   15.4   25.0   36.7   49.4   678      15.4   2.10   0.343
                                                      Visit 1   401   100        2.20   9.89   15.6   25.1   36.4   45.1   678      15.8   2.12   
                                                      Visit 3   270   100        1.87   9.61   14.9   23.8   36.9   51.1   154      14.9   2.07   
  mEHHP                                               Total     670   99         0.67   5.14   8.87   14.6   22.9   30.1   800      8.50   2.38   0.304
                                                      Visit 1   401   99         0.75   5.44   9.24   15.5   22.9   31.6   800      8.96   2.38   
                                                      Visit 3   269   99         0.67   4.53   8.43   14.0   22.0   29.8   82.9     7.85   2.37   
  mEHP                                                Total     669   85         0.28   1.50   2.80   4.61   7.51   10.1   433      2.72   2.34   0.701
                                                      Visit 1   400   88         0.43   1.57   2.86   4.60   7.61   10.8   433      2.83   2.34   
                                                      Visit 3   269   82         0.28   1.43   2.67   4.70   7.08   9.41   34.5     2.57   2.32   
  mEOHP                                               Total     668   99         0.50   4.42   7.57   12.4   18.8   23.4   531      7.27   2.29   0.739
                                                      Visit 1   399   99         0.50   4.45   7.50   12.5   19.1   21.8   531      7.36   2.32   
                                                      Visit 3   269   100        0.67   4.40   7.65   12.4   18.4   25.2   65.2     7.14   2.25   
  mEP                                                 Total     666   99         2.00   15.9   39.3   163    527    920    43,000   53.8   4.94   0.895
                                                      Visit 1   398   99         2.00   18.3   39.6   150    526    846    43,000   54.4   4.75   
                                                      Visit 3   268   99         2.43   13.6   36.0   206    526    962    7765     52.9   5.25   
  miBP                                                Total     670   99         0.75   6.11   11.2   20.6   37.9   51.0   204      11.4   2.50   0.789
                                                      Visit 1   400   99         0.75   6.28   10.8   21.0   39.4   51.1   202      11.3   2.51   
                                                      Visit 3   270   99         1.33   6.00   12.1   20.0   37.7   49.3   204      11.6   2.48   
  MCOCH                                               Total     445   18         0.20   0.34   0.42   0.59   0.88   1.41   7.26     0.47   1.71   0.091
                                                      Visit 1   273   19         0.20   0.32   0.39   0.54   0.88   1.26   7.26     0.45   1.71   
                                                      Visit 3   172   17         0.21   0.35   0.47   0.60   1.01   1.43   3.54     0.51   1.71   
  MHBP                                                Total     443   81         0.21   0.80   1.54   2.82   5.58   8.67   26.2     1.52   2.64   0.385
                                                      Visit 1   271   84         0.24   0.81   1.62   2.98   5.50   9.13   26.2     1.58   2.69   
                                                      Visit 3   172   77         0.21   0.72   1.46   2.47   5.58   8.12   22.8     1.44   2.56   
  MHiBP                                               Total     445   97         0.35   2.82   5.00   9.75   16.5   23.2   51.1     5.10   2.47   0.865
                                                      Visit 1   273   98         0.35   2.83   5.16   10.3   17.0   23.7   51.1     5.34   2.46   
                                                      Visit 3   172   96         0.44   2.75   4.84   9.20   13.1   22.8   48.7     4.75   2.48   
  MHiNCH                                              Total     612   33         0.16   0.28   0.38   0.67   1.14   1.78   21.0     0.47   2.04   0.056
                                                      Visit 1   367   35         0.16   0.27   0.38   0.67   1.13   1.67   21.0     0.46   2.05   
                                                      Visit 3   245   31         0.19   0.28   0.40   0.67   1.20   1.98   8.00     0.48   2.03   
  mNP                                                 Total     444   29         0.35   0.64   0.85   1.46   3.18   6.36   42.9     1.08   2.21   0.846
                                                      Visit 1   271   34         0.41   0.64   0.85   1.59   3.60   7.16   42.9     1.10   2.26   
                                                      Visit 3   173   22         0.35   0.64   0.85   1.41   2.80   5.05   33.0     1.06   2.13   
  MECPTP                                              Total     153   100        1.13   7.77   15.3   33.3   162    443    2543     20.5   3.99   0.691
                                                      Visit 1   92    100        1.22   7.94   14.9   36.4   140    495    2543     20.9   4.09   
                                                      Visit 3   61    100        1.13   7.77   16.2   28.8   167    342    732      20.0   3.89   
  MEHHTP                                              Total     153   97         0.25   1.68   2.86   6.00   23.0   51.9   1207     3.72   3.64   0.328
                                                      Visit 1   92    99         0.25   1.73   2.81   5.93   22.3   65.0   1207     3.82   3.79   
                                                      Visit 3   61    95         0.35   1.46   2.91   7.85   23.6   37.7   97.7     3.58   3.46   
  MONP                                                Total     153   93         0.28   1.13   2.21   3.84   6.63   11.7   127      2.19   2.83   0.399
                                                      Visit 1   92    95         0.28   1.12   2.19   4.68   8.07   11.8   34.5     2.29   2.79   
                                                      Visit 3   61    90         0.31   1.20   2.21   2.83   4.43   8.45   127      2.04   2.92   

All phthalate concentrations have been adjusted for specific gravity and are presented in ng/mL. Boldface type indicates a significant *P* value \< 0.05.

Abbreviations: GM, geometric mean; GSD, geometric SD; T, testosterone.

*P* value was calculated using a paired *t* test between biomarker concentrations at visit1 and visit 3. Skewed biomarkers were log transformed to achieve normality.

Units pg/mL.

Units ng/mL.

Units nmol/L.

Units uIU/mL.

Units ng/dL.

Units μg/dL.

During the duration of the study, number of children, smoking status, and alcohol use did not show significant associations with most phthalate metabolites and hormones assessed. Categorical maternal age and ordinal maternal education were significantly associated with the largest number of phthalate metabolites and hormones and thus were retained in final models. Employment status and annual household income were both significantly associated with most hormones but were highly correlated with maternal education (*R* = 0.560, *P* \< 0.001 and *R* = 0.571, *P* \< 0.001, respectively; data not shown) and thus were not considered in further analyses. Self-reported environmental tobacco smoke exposure was also associated with many phthalate metabolites but was not associated with most hormones and was not considered in further analyses.

B. CRH and Reproductive Hormones {#s16}
--------------------------------

Results from linear mixed models indicating associations between phthalate metabolite biomarkers and serum hormones over the study period are shown in [Table 2](#tbl2){ref-type="table"}, whereas visit-specific results are shown in [Table 3](#tbl3){ref-type="table"}. Further linear mixed effects analyses were conducted on a subset of PROTECT women who provided biomarker data at both clinic visits, for which results are shown in an online repository \[[@B71]\]. A decrease in CRH concentration was associated with IQR increases in MCNP (%*Δ*, −4.08; 95% CI, −7.24, −0.804), MCPP (%*Δ*, −5.25; 95% CI, −8.26, −2.14), MECPP (%*Δ*, −18.4; 95% CI, −30.4, −4.37), MEHHP (%*Δ*, −13.4; 95% CI, −22.7, −2.92), and MEOHP (%*Δ*, −12.7; 95% CI, −22.2, −2.20) over the study period. IQR increases in MCPP were associated with decreases in CRH concentrations at both visit 1 (%*Δ*, −5.46; 95% CI, −9.22, −1.55) and visit 3 (%*Δ*, −4.98; 95% CI, −9.22, −0.544). At visit 3 only, decreases in CRH concentrations were associated with IQR increases in MECPP (%*Δ*, −24.0; 95% CI, −38.7, −5.87), MEHHP (%*Δ*, −18.0; 95% CI, −29.8, −4.17), and MEOHP (%*Δ*, −15.8; 95% CI, −28.0, −1.63).

###### 

Results From Linear Mixed Models Showing the Percent Change in Serum Hormone Levels Corresponding to an IQR Increase in Urinary Phthalate Metabolite Concentrations

           CRH[*^a^*](#tblfn8){ref-type="table-fn"}   E3[*^a^*](#tblfn8){ref-type="table-fn"}   SHBG                                                                                                                                                   
  -------- ------------------------------------------ ----------------------------------------- ----------------------------------------------------- ------- ----- --------------------- ------- ------- ----- -------------------------- ----------- -------
  MBP      652                                        −8.57 (−21.0, 5.77)                       0.230                                                 0.893   652   −2.14 (−15.1, 12.8)   0.766   0.916   652   −2.85 (−10.8, 5.1)         0.483       0.404
  MBzP     648                                        −5.45 (−11.5, 1.05)                       0.101                                                 0.792   648   −4.74 (−10.7, 1.62)   0.143   0.220   648   −1.64 (−5.42, 2.13)        0.395       0.715
  MCNP     643                                        **−4.08 (−7.24, −0.80)**                  **0.016** [***^b^***](#tblfn9){ref-type="table-fn"}   0.923   643   1.39 (−1.93, 4.82)    0.418   1.000   643   −0.97 (−2.76, 0.81)        0.288       0.907
  MCOP     644                                        −6.16 (−15.3, 3.95)                       0.225                                                 0.505   644   −0.76 (−10.2, 9.66)   0.881   0.250   644   **−5.66 (−11.2, −0.08)**   **0.049**   0.781
  MCPP     646                                        **−5.25 (−8.26, −2.14)**                  **0.001** [***^b^***](#tblfn9){ref-type="table-fn"}   0.861   646   0.70 (−2.44, 3.94)    0.669   0.928   646   −1.24 (−2.99, 0.51)        0.167       0.642
  MECPP    649                                        **−18.4 (−30.4, −4.37)**                  **0.013** [***^b^***](#tblfn9){ref-type="table-fn"}   0.334   649   −0.30 (−14.6, 16.4)   0.970   0.485   649   −2.46 (−11.3, 6.42)        0.588       0.411
  MEHHP    648                                        **−13.4 (−22.7, −2.92)**                  **0.015** [***^b^***](#tblfn9){ref-type="table-fn"}   0.315   648   −4.85 (−14.9, 6.4)    0.385   0.757   648   −4.38 (−10.6, 1.83)        0.169       0.697
  MEHP     647                                        −5.15 (−10.5, 0.57)                       0.079                                                 0.414   647   −1.56 (−7.06, 4.27)   0.593   0.292   647   −0.11 (−3.38, 3.16)        0.948       0.407
  MEOHP    646                                        **−12.7 (−22.2, −2.2)**                   **0.020** [***^b^***](#tblfn9){ref-type="table-fn"}   0.508   646   −1.74 (−12.1, 9.91)   0.760   0.575   646   −3.10 (−9.30, 3.10)        0.329       0.598
  MEP      644                                        −1.3 (−13.2, 12.2)                        0.841                                                 0.584   644   6.09 (−6.32, 20.1)    0.353   0.400   644   −1.53 (−8.70, 5.64)        0.676       0.849
  MiBP     648                                        0.91 (−11.6, 15.2)                        0.894                                                 0.878   648   −7.07 (−18.2, 5.55)   0.261   0.777   648   −2.85 (−10.3, 4.60)        0.455       0.875
  MHBP     435                                        0.08 (−4.43, 4.81)                        0.972                                                 0.674   435   0.93 (−3.4, 5.46)     0.680   0.954   435   −0.98 (−3.44, 1.48)        0.437       0.354
  MHiBP    437                                        −1.46 (−11.7, 10.0)                       0.794                                                 0.730   437   −0.51 (−10.5, 10.6)   0.925   0.417   437   −2.94 (−9.31, 3.43)        0.368       0.660
  MECPTP   153                                        9.18 (−5.64, 26.3)                        0.247                                                 0.391   153   0.87 (−14.8, 19.4)    0.921   0.074   153   −2.54 (−10.1, 4.98)        0.513       0.058
  MEHHTP   153                                        6.47 (−2.43, 16.2)                        0.169                                                 0.912   153   −0.79 (−10.3, 9.78)   0.879   0.109   153   −1.35 (−6.12, 3.42)        0.583       0.156
  MONP     153                                        2.15 (−4.14, 8.86)                        0.516                                                 0.627   153   −0.42 (−7.44, 7.14)   0.911   0.700   153   0.26 (−3.11, 3.62)         0.881       0.995

           **Progesterone** [*^a^*](#tblfn8){ref-type="table-fn"}   **TSH** [*^a^*](#tblfn8){ref-type="table-fn"}   **fT4**                                                                                                                                               
  -------- -------------------------------------------------------- ----------------------------------------------- ----------- ------- ----- --------------------- ------- ------- ----- ------------------------- ----------------------------------------------------- -------
  MBP      652                                                      2.73 (−8.84, 15.8)                              0.659       0.110   644   3.94 (−12.2, 23)      0.653   0.483   652   **3.39 (0.11, 6.67)**     **0.044**                                             0.685
  MBzP     648                                                      −2.28 (−7.47, 3.2)                              0.408       0.936   639   0.26 (−7.54, 8.72)    0.949   0.720   647   1.28 (−0.25, 2.81)        0.102                                                 0.364
  MCNP     643                                                      −2.49 (−5.15, 0.25)                             0.076       0.562   635   −0.07 (−3.70, 3.69)   0.968   0.704   643   0.51 (−0.24, 1.25)        0.187                                                 0.520
  MCOP     644                                                      **−9.85 (−17.0, −2.03)**                        **0.016**   0.739   636   2.23 (−9.08, 14.9)    0.713   0.811   644   **3.03 (0.74, 5.33)**     **0.011** [***^b^***](#tblfn9){ref-type="table-fn"}   0.070
  MCPP     646                                                      −1.73 (−4.29, 0.90)                             0.197       0.652   638   1.34 (−2.31, 5.13)    0.479   0.747   646   **1.31 (0.59, 2.03)**     **0.000** [***^b^***](#tblfn9){ref-type="table-fn"}   0.155
  MECPP    649                                                      −8.48 (−19.6, 4.19)                             0.182       0.850   641   16.4 (−3.59, 40.5)    0.116   0.983   649   1.55 (−2.08, 5.19)        0.404                                                 0.727
  MEHHP    648                                                      −5.08 (−13.5, 4.19)                             0.275       0.661   640   10.7 (−2.89, 26.3)    0.130   0.939   648   0.78 (−1.79, 3.36)        0.552                                                 0.904
  MEHP     647                                                      −1.17 (−5.81, 3.69)                             0.631       0.846   639   1.76 (−5.06, 9.07)    0.623   0.722   647   0.64 (−0.70, 1.98)        0.349                                                 0.935
  MEOHP    646                                                      −3.04 (−11.7, 6.45)                             0.518       0.680   638   11.4 (−2.19, 26.9)    0.106   0.985   646   1.19 (−1.38, 3.76)        0.364                                                 0.899
  MEP      644                                                      −4.91 (−14.3, 5.48)                             0.343       0.240   636   −11.9 (−24.4, 2.61)   0.105   0.588   644   0.642 (−2.28, 3.57)       0.668                                                 0.142
  MiBP     648                                                      −1.08 (−11.1, 10.1)                             0.843       0.684   640   5.24 (−10.3, 23.4)    0.531   0.544   648   0.61 (−2.43, 3.65)        0.695                                                 0.787
  MHBP     435                                                      −0.86 (−4.47, 2.89)                             0.649       0.250   433   1.93 (−3.75, 7.95)    0.514   0.962   435   **1.11 (−0.004, 2.22)**   **0.054**                                             0.219
  MHiBP    437                                                      −7.19 (−15.0, 1.37)                             0.101       0.340   435   6.2 (−8.05, 22.7)     0.416   0.481   437   0.54 (−2.18, 3.27)        0.696                                                 0.242
  MECPTP   153                                                      −7.43 (−18.4, 5.07)                             0.241       0.195   153   −0.72 (−17.7, 19.7)   0.940   0.370   153   1.99 (−2.15, 6.14)        0.353                                                 0.972
  MEHHTP   153                                                      −7.3 (−14.1, 0.045)                             0.060       0.129   153   0.64 (−10.6, 13.3)    0.917   0.512   153   0.75 (−1.75, 3.24)        0.561                                                 0.818
  MONP     153                                                      0.84 (−4.64, 6.62)                              0.772       0.954   153   −3.01 (−10.7, 5.31)   0.472   0.560   153   0.24 (−1.56, 2.05)        0.793                                                 0.585

           **T3**   **T4**                   **Testosterone** [*^a^*](#tblfn8){ref-type="table-fn"}                                                                                                                                                    
  -------- -------- ------------------------ -------------------------------------------------------- ------- ----- ----------------------- ----------------------------------------------------- ------- ----- -------------------------- ----------- -----------
  MBP      650      **6.19 (1.70, 10.7)**    **0.008** [***^b^***](#tblfn9){ref-type="table-fn"}      0.591   651   **4.61 (0.25, 8.96)**   **0.040**                                             0.815   648   9.49 (−4.45, 25.5)         0.194       0.681
  MBzP     645      **2.18 (0.042, 4.32)**   **0.048** [***^b^***](#tblfn9){ref-type="table-fn"}      0.701   646   1.97 (−0.10, 4.03)      0.064                                                 0.325   643   1.53 (−4.85, 8.35)         0.647       0.156
  MCNP     641      0.88 (−0.11, 1.87)       0.083                                                    0.907   642   0.46 (−0.51, 1.44)      0.351                                                 0.963   639   −0.23 (−3.26, 2.90)        0.885       **0.026**
  MCOP     642      **5.24 (2.13, 8.35)**    **0.001** [***^b^***](#tblfn9){ref-type="table-fn"}      0.633   643   **4.02 (1.00, 7.03)**   **0.010** [***^b^***](#tblfn9){ref-type="table-fn"}   0.553   640   5.46 (−4.13, 16.0)         0.276       **0.004**
  MCPP     644      **1.88 (0.91, 2.86)**    **0.000** [***^b^***](#tblfn9){ref-type="table-fn"}      0.953   645   **1.85 (0.91, 2.79)**   **0.000** [***^b^***](#tblfn9){ref-type="table-fn"}   0.539   642   −1.46 (−4.35, 1.53)        0.337       0.163
  MECPP    647      **10.6 (5.63, 15.6)**    **0.000** [***^b^***](#tblfn9){ref-type="table-fn"}      0.382   648   2.36 (−2.50, 7.23)      0.342                                                 0.985   645   −8.77 (−21.7, 6.28)        0.241       0.214
  MEHHP    646      **5.05 (1.55, 8.56)**    **0.005** [***^b^***](#tblfn9){ref-type="table-fn"}      0.468   647   0.16 (−3.25, 3.57)      0.927                                                 0.801   644   −2.69 (−12.6, 8.30)        0.618       0.202
  MEHP     645      1.45 (−0.38, 3.29)       0.123                                                    0.132   646   0.87 (−0.92, 2.66)      0.343                                                 0.863   643   1.32 (−4.22, 7.18)         0.648       0.228
  MEOHP    644      **5.94 (2.45, 9.43)**    **0.001** [***^b^***](#tblfn9){ref-type="table-fn"}      0.494   645   1.20 (−2.20, 4.60)      0.489                                                 0.734   642   −1.39 (−11.4, 9.72)        0.798       0.177
  MEP      642      3.21 (−0.84, 7.26)       0.122                                                    0.997   643   0.09 (−3.82, 3.99)      0.965                                                 0.394   640   **−14.5 (−24.3, −3.42)**   **0.013**   0.443
  MiBP     646      **4.43 (0.21, 8.66)**    **0.041** [***^b^***](#tblfn9){ref-type="table-fn"}      0.510   647   −0.67 (−4.74, 3.40)     0.747                                                 0.639   644   −0.84 (−12.7, 12.7)        0.897       0.319
  MHBP     435      **1.53 (0.031, 3.03)**   **0.048** [***^b^***](#tblfn9){ref-type="table-fn"}      0.575   435   0.45 (−1.03, 1.92)      0.556                                                 0.480   436   **4.71 (0.27, 9.35)**      **0.040**   0.902
  MHiBP    437      **4.9 (1.13, 8.67)**     **0.012** [***^b^***](#tblfn9){ref-type="table-fn"}      0.913   437   −1.03 (−4.67, 2.61)     0.581                                                 0.596   438   1.44 (−8.88, 12.9)         0.794       0.121
  MECPTP   153      2.6 (−2.92, 8.11)        0.363                                                    0.527   153   1.34 (−3.67, 6.35)      0.604                                                 0.121   153   2.15 (−13.1, 20.1)         0.798       0.639
  MEHHTP   153      2.39 (−0.96, 5.74)       0.171                                                    0.653   153   0.72 (−2.33, 3.77)      0.648                                                 0.247   153   0.38 (−9.00, 10.7)         0.940       0.542
  MONP     153      **2.88 (0.49, 5.27)**    **0.025** [***^b^***](#tblfn9){ref-type="table-fn"}      0.277   153   1.08 (−1.09, 3.25)      0.337                                                 0.998   153   −2.84 (−9.43, 4.23)        0.427       0.146

           **Progesterone/E3** [*^a^*](#tblfn8){ref-type="table-fn"}   **T3/T4**                                                                                          
  -------- ----------------------------------------------------------- ------------------------- ----------- ------- ----- ----------------------- ----------- ------- -- --
  MBP      652                                                         5.33 (−8.08, 20.7)        0.456       0.113   649   1.14 (−4.04, 6.32)      0.666       0.507      
  MBzP     648                                                         2.63 (−3.61, 9.26)        0.419       0.155   644   0.18 (−2.27, 2.63)      0.886       0.203      
  MCNP     643                                                         **−3.8 (−6.78, −0.73)**   **0.017**   0.634   640   0.41 (−0.75, 1.57)      0.493       0.891      
  MCOP     644                                                         −9.02 (−17.4, 0.15)       0.055       0.283   641   1.41 (−2.21, 5.03)      0.446       0.961      
  MCPP     646                                                         −2.28 (−5.2, 0.72)        0.137       0.742   643   0.06 (−1.08, 1.19)      0.923       0.895      
  MECPP    649                                                         −8.1 (−20.9, 6.75)        0.271       0.358   646   **7.79 (2.06, 13.5)**   **0.009**   0.645      
  MEHHP    648                                                         −0.18 (−10.3, 11.1)       0.974       0.502   645   **4.68 (0.64, 8.73)**   **0.025**   0.962      
  MEHP     647                                                         0.54 (−4.88, 6.26)        0.850       0.185   644   0.31 (−1.81, 2.43)      0.776       0.505      
  MEOHP    646                                                         −1.05 (−11.1, 10.1)       0.847       0.334   643   **4.58 (0.55, 8.61)**   **0.027**   0.956      
  MEP      644                                                         −9.63 (−19.8, 1.86)       0.099       0.871   641   3.15 (−1.49, 7.78)      0.186       0.521      
  MiBP     648                                                         6.53 (−5.89, 20.6)        0.319       0.978   645   4.75 (−0.07, 9.56)      0.055       0.732      
  MHBP     435                                                         −1.66 (−5.75, 2.61)       0.443       0.335   435   0.96 (−0.86, 2.77)      0.304       0.301      
  MHiBP    437                                                         −6.64 (−15.8, 3.54)       0.196       0.799   437   **4.97 (0.50, 9.44)**   **0.032**   0.704      
  MECPTP   153                                                         −5.33 (-19.5, 11.4)       0.513       0.531   153   1.32 (−4.62, 7.25)      0.667       0.298      
  MEHHTP   153                                                         −4.81 (−13.6, 4.92)       0.328       0.822   153   1.49 (−2.14, 5.12)      0.426       0.356      
  MONP     153                                                         0.92 (−5.96, 8.29)        0.802       0.950   153   1.66 (−0.94, 4.27)      0.220       0.289      

All models were adjusted for categorical maternal age, ordinal maternal education, study visit, and specific gravity. Visit *P* indicates significance of an interaction term between study visit and log(phthalate). Boldface type indicates a 95% CI.

Hormone levels were natural log-transformed for all analyses.

Associations between phthalates and hormones that have a *q* value \<0.1.

###### 

Results From Linear Mixed Models Showing the Percent Change in Serum Hormone Levels Corresponding to an IQR Increase in Urinary Phthalate Metabolite Concentrations Specific to Each Study Visit

                     CRH[*^a^*](#tblfn10){ref-type="table-fn"}   E3[*^a^*](#tblfn10){ref-type="table-fn"}   SHBG                                                                          
  -------- --------- ------------------------------------------- ------------------------------------------ ----------- ----- ---------------------- ------- ----- ---------------------- -------
  MBP      Visit 1   652                                         −9.14 (−23.5, 7.89)                        0.276       652   −1.67 (−16.9, 16.3)    0.845   652   −0.711 (−10.1, 8.7)    0.882
           Visit 3   652                                         −7.76 (−24.1, 12)                          0.417       652   −2.82 (−19.8, 17.7)    0.770   652   −5.57 (−15.7, 4.61)    0.285
  MBzP     Visit 1   648                                         −5.97 (−13, 1.67)                          0.125       648   −2.29 (−9.47, 5.46)    0.553   648   −2.05 (−6.44, 2.33)    0.360
           Visit 3   648                                         −4.63 (−13.1, 4.63)                        0.318       648   −8.54 (−16.5, 0.208)   0.057   648   −1.07 (−5.94, 3.8)     0.667
  MCNP     Visit 1   643                                         −3.95 (−7.93, 0.198)                       0.064       643   1.39 (−2.78, 5.73)     0.521   643   −1.06 (−3.34, 1.23)    0.366
           Visit 3   643                                         −4.23 (−8.65, 0.398)                       0.075       643   1.39 (−3.29, 6.29)     0.569   643   −0.876 (−3.29, 1.54)   0.478
  MCOP     Visit 1   644                                         −3.84 (−15.1, 8.95)                        0.540       644   −4.8 (−15.8, 7.58)     0.431   644   −6.22 (−13, 0.587)     0.075
           Visit 3   644                                         −9.66 (−22.4, 5.11)                        0.191       644   5.98 (−8.75, 23.1)     0.448   644   −4.9 (−12.6, 2.83)     0.216
  MCPP     Visit 1   **646**                                     **−5.46 (−9.22, −1.55)**                   **0.007**   646   0.583 (−3.35, 4.68)    0.776   646   −0.93 (−3.12, 1.26)    0.405
           Visit 3   **646**                                     **−4.98 (−9.22, −0.544)**                  **0.030**   646   0.843 (−3.61, 5.5)     0.716   646   −1.6 (−3.93, 0.724)    0.179
  MECPP    Visit 1   649                                         −14.2 (−29, 3.55)                          0.112       649   3.33 (−14.1, 24.3)     0.729   649   −0.15 (−10.6, 10.3)    0.978
           Visit 3   **649**                                     **−24 (−38.7, −5.87)**                     **0.013**   649   −5.29 (−23.4, 17)      0.615   649   −5.47 (−16.9, 5.94)    0.349
  MEHHP    Visit 1   648                                         −9.92 (−21.5, 3.3)                         0.137       648   −3.72 (−15.8, 10.1)    0.582   648   −3.55 (−11, 3.94)      0.355
           Visit 3   **648**                                     **−18 (−29.8, −4.17)**                     **0.014**   648   −6.42 (−19.7, 9.11)    0.398   648   −5.44 (−13.6, 2.74)    0.194
  MEHP     Visit 1   647                                         −3.63 (−10.1, 3.33)                        0.300       647   0.475 (−6.22, 7.65)    0.893   647   0.76 (−3.1, 4.62)      0.700
           Visit 3   647                                         −7.44 (−14.8, 0.536)                       0.069       647   −4.63 (−12.2, 3.53)    0.260   647   −1.32 (−5.67, 3.02)    0.551
  MEOHP    Visit 1   646                                         −10.6 (−21.9, 2.31)                        0.106       646   0.269 (−12.2, 14.5)    0.968   646   −2.02 (−9.4, 5.35)     0.591
           Visit 3   **646**                                     **−15.8 (−28, −1.63)**                     **0.032**   646   −4.67 (−18.3, 11.2)    0.544   646   −4.53 (−12.7, 3.64)    0.279
  MEP      Visit 1   644                                         −4.07 (−18.5, 12.9)                        0.618       644   1.63 (−13.4, 19.2)     0.843   644   −2.05 (−10.9, 6.84)    0.652
           Visit 3   644                                         2.2 (−14.6, 22.3)                          0.813       644   12 (−6.15, 33.6)       0.211   644   −0.926 (−10.5, 8.6)    0.849
  MiBP     Visit 1   648                                         1.57 (−13.1, 18.8)                         0.845       648   −8.18 (−21.1, 6.9)     0.273   648   −3.19 (−11.8, 5.39)    0.468
           Visit 3   648                                         −0.0167 (−16.2, 19.3)                      0.999       648   −5.49 (−20.5, 12.3)    0.522   648   −2.37 (−11.9, 7.11)    0.625
  MHBP     Visit 1   435                                         −0.502 (−5.7, 4.98)                        0.854       435   1.01 (−4.01, 6.29)     0.700   435   −1.71 (−4.62, 1.2)     0.253
           Visit 3   435                                         1.1 (−5.33, 7.96)                          0.746       435   0.805 (−5.24, 7.23)    0.800   435   −0.113 (−3.17, 2.94)   0.943
  MHiBP    Visit 1   437                                         −2.59 (−14.3, 10.8)                        0.690       437   2.11 (−9.66, 15.4)     0.740   437   −3.62 (−10.7, 3.47)    0.319
           Visit 3   437                                         0.23 (−13.4, 16)                           0.975       437   −4.13 (−16.5, 10.1)    0.551   437   −2.04 (−9.54, 5.46)    0.595
  MECPTP   Visit 1   153                                         14.2 (−4.82, 37.1)                         0.163       153   14.1 (−7.42, 40.7)     0.225   153   3.65 (−5.96, 13.3)     0.462
           Visit 3   153                                         0.471 (−20.3, 26.7)                        0.969       153   −16.5 (−35.9, 8.88)    0.193   153   −9.19 (−19, 0.598)     0.075
  MEHHTP   Visit 1   153                                         6.82 (−3.99, 18.8)                         0.235       153   5.49 (−6.68, 19.3)     0.399   153   1.49 (−4.59, 7.56)     0.635
           Visit 3   153                                         5.81 (−7.72, 21.3)                         0.425       153   −10.1 (−23.2, 5.16)    0.193   153   −4.39 (−10.6, 1.83)    0.177
  MONP     Visit 1   153                                         3.46 (−4.59, 12.2)                         0.417       153   −1.56 (−10.3, 8.08)    0.744   153   0.23 (−4.32, 4.78)     0.922
           Visit 3   153                                         0.52 (−8.24, 10.1)                         0.912       153   1.07 (−8.97, 12.2)     0.844   153   0.25 (−4.18, 4.68)     0.913

                     **Progesterone** [***^a^***](#tblfn10){ref-type="table-fn"}   **TSH** [***^a^***](#tblfn10){ref-type="table-fn"}   **fT4**                                                                             
  -------- --------- ------------------------------------------------------------- ---------------------------------------------------- ----------- ----- ---------------------- ------- --------- ------------------------ -----------
  MBP      Visit 1   652                                                           −3.36 (−16, 11.2)                                    0.634       644   −0.142 (−18.4, 22.2)   0.989   652       3.81 (−0.0488, 7.68)     0.055
           Visit 3   652                                                           12.1 (−4.46, 31.6)                                   0.163       644   8.75 (−12, 34.4)       0.438   652       2.82 (−1.44, 7.09)       0.196
  MBzP     Visit 1   648                                                           −2.41 (−8.49, 4.07)                                  0.458       639   −0.617 (−9.56, 9.21)   0.898   647       1.71 (−0.0698, 3.49)     0.062
           Visit 3   648                                                           −2.06 (−9.29, 5.74)                                  0.596       639   1.4 (−8.42, 12.3)      0.790   647       0.666 (−1.37, 2.7)       0.522
  MCNP     Visit 1   643                                                           −3.11 (−6.44, 0.332)                                 0.078       635   0.51 (−4.17, 5.42)     0.835   643       0.697 (−0.25, 1.64)      0.151
           Visit 3   643                                                           −1.69 (−5.48, 2.25)                                  0.396       635   −0.697 (−5.46, 4.3)    0.780   643       0.275 (−0.748, 1.3)      0.599
  MCOP     Visit 1   **644**                                                       **−10.8 (−19.4, −1.19)**                             **0.030**   636   3.27 (−10.6, 19.2)     0.662   **644**   **4.51 (1.73, 7.29)**    **0.002**
           Visit 3   644                                                           −8.43 (−19.1, 3.71)                                  0.168       636   0.905 (−13.9, 18.2)    0.911   644       0.903 (−2.33, 4.14)      0.585
  MCPP     Visit 1   646                                                           −2.19 (−5.39, 1.12)                                  0.194       638   0.88 (−3.63, 5.6)      0.708   **646**   **1.7 (0.808, 2.59)**    **0.000**
           Visit 3   646                                                           −1.13 (−4.77, 2.66)                                  0.556       638   1.86 (−2.92, 6.87)     0.454   646       0.834 (−0.135, 1.8)      0.094
  MECPP    Visit 1   649                                                           −9.21 (−22.2, 5.92)                                  0.221       641   16.3 (−6.85, 45.1)     0.185   649       1.96 (−2.33, 6.24)       0.372
           Visit 3   649                                                           −7.42 (−22.4, 10.4)                                  0.392       641   16.6 (−8.11, 47.9)     0.208   649       1 (−3.76, 5.76)          0.680
  MEHHP    Visit 1   648                                                           −6.39 (−16.3, 4.72)                                  0.250       640   11.1 (−5.18, 30.3)     0.195   648       0.89 (−2.21, 3.99)       0.575
           Visit 3   648                                                           −3.2 (−14.8, 9.99)                                   0.619       640   10.3 (−6.99, 30.8)     0.262   648       0.643 (−2.79, 4.08)      0.715
  MEHP     Visit 1   647                                                           −1.48 (−6.98, 4.35)                                  0.612       639   0.949 (−6.99, 9.57)    0.821   647       0.679 (−0.911, 2.27)     0.404
           Visit 3   647                                                           −0.695 (−7.26, 6.33)                                 0.842       639   2.83 (−6.06, 12.5)     0.546   647       0.592 (−1.23, 2.42)      0.525
  MEOHP    Visit 1   646                                                           −4.23 (−14.2, 6.96)                                  0.445       638   11.3 (−4.68, 30.1)     0.178   646       1.3 (−1.75, 4.34)        0.404
           Visit 3   646                                                           −1.23 (−13.1, 12.3)                                  0.851       638   11.5 (−5.81, 32.1)     0.208   646       1.05 (−2.39, 4.48)       0.552
  MEP      Visit 1   644                                                           −9.55 (−20.8, 3.28)                                  0.140       636   −14.6 (−29.3, 3.12)    0.103   644       2.29 (−1.36, 5.93)       0.221
           Visit 3   644                                                           1.17 (−12.6, 17.1)                                   0.877       636   −8.85 (−25.2, 11.1)    0.360   644       −1.35 (−5.3, 2.59)       0.503
  MiBP     Visit 1   648                                                           −2.48 (−14.1, 10.7)                                  0.699       640   2.34 (−14.8, 22.9)     0.805   648       0.359 (−3.17, 3.89)      0.843
           Visit 3   648                                                           0.931 (−12.6, 16.6)                                  0.900       640   9.12 (−10.5, 33)       0.389   648       0.953 (−2.98, 4.88)      0.635
  MHBP     Visit 1   435                                                           −2.13 (−6.26, 2.18)                                  0.329       433   1.84 (−4.78, 8.93)     0.596   435       0.685 (−0.606, 1.98)     0.301
           Visit 3   435                                                           1.37 (−3.85, 6.86)                                   0.615       433   2.05 (−5.29, 9.96)     0.595   **435**   **1.75 (0.235, 3.27)**   **0.026**
  MHiBP    Visit 1   437                                                           −4.74 (−14.1, 5.61)                                  0.359       435   9.08 (−7.27, 28.3)     0.297   437       −0.356 (−3.47, 2.76)     0.823
           Visit 3   437                                                           −10.6 (−20.4, 0.485)                                 0.063       435   2.42 (−14.1, 22.1)     0.790   437       1.85 (−1.62, 5.32)       0.300
  MECPTP   Visit 1   153                                                           −0.868 (−15.6, 16.4)                                 0.916       153   −7.85 (−27.9, 17.8)    0.518   153       2.04 (−3.15, 7.24)       0.447
           Visit 3   153                                                           −15.7 (−30.2, 1.97)                                  0.089       153   7.36 (−16.6, 38.2)     0.585   153       1.9 (−4.64, 8.43)        0.573
  MEHHTP   Visit 1   153                                                           −3.01 (−11.7, 6.57)                                  0.530       153   −2.6 (−16.4, 13.4)     0.737   153       0.541 (−2.51, 3.59)      0.730
           Visit 3   **153**                                                       **−13.1 (−22.3, −2.75)**                             **0.020**   153   4.19 (−11, 21.9)       0.612   153       1.1 (−2.78, 4.98)        0.583
  MONP     Visit 1   153                                                           0.687 (−6.36, 8.26)                                  0.854       153   −0.835 (−11.2, 10.8)   0.883   153       0.655 (−1.65, 2.96)      0.581
           Visit 3   153                                                           0.989 (−6.59, 9.18)                                  0.806       153   −5 (−14.7, 5.8)        0.358   153       −0.263 (−2.84, 2.31)     0.842

                     **T3**    **T4**                   **Testosterone** [***^a^***](#tblfn10){ref-type="table-fn"}                                                                                     
  -------- --------- --------- ------------------------ ------------------------------------------------------------- --------- ------------------------ ----------- --------- ------------------------ -----------
  MBP      Visit 1   **650**   **5.42 (0.108, 10.7)**   **0.047**                                                     651       4.94 (−0.208, 10.1)      0.062       648       11.5 (−5.12, 31.1)       0.188
           Visit 3   **650**   **7.17 (1.47, 12.9)**    **0.015**                                                     651       4.2 (−1.36, 9.76)        0.141       648       7.03 (−10.1, 27.4)       0.446
  MBzP     Visit 1   645       1.93 (−0.552, 4.42)      0.129                                                         **646**   **2.58 (0.181, 4.98)**   **0.037**   643       4.39 (−3.17, 12.5)       0.265
           Visit 3   645       2.51 (−0.207, 5.23)      0.072                                                         646       1.13 (−1.51, 3.78)       0.403       643       −2.33 (−10.2, 6.24)      0.584
  MCNP     Visit 1   641       0.929 (−0.342, 2.2)      0.154                                                         642       0.482 (−0.762, 1.73)     0.449       639       2.62 (−1.33, 6.73)       0.199
           Visit 3   641       0.829 (−0.494, 2.15)     0.221                                                         642       0.443 (−0.866, 1.75)     0.508       639       −3.34 (−7.25, 0.734)     0.109
  MCOP     Visit 1   **642**   **5.78 (1.97, 9.59)**    **0.003**                                                     **643**   **4.66 (0.978, 8.34)**   **0.014**   **640**   **16.5 (3.83, 30.7)**    **0.010**
           Visit 3   **642**   **4.53 (0.284, 8.79)**   **0.038**                                                     643       3.16 (−0.99, 7.3)        0.138       640       −7.77 (−19, 5)           0.223
  MCPP     Visit 1   **644**   **1.91 (0.69, 3.12)**    **0.003**                                                     **645**   **2.07 (0.896, 3.24)**   **0.001**   642       0.156 (−3.52, 3.98)      0.935
           Visit 3   **644**   **1.86 (0.572, 3.15)**   **0.005**                                                     **645**   **1.59 (0.351, 2.84)**   **0.013**   642       −3.25 (−6.99, 0.637)     0.102
  MECPP    Visit 1   **647**   **9.26 (3.4, 15.1)**     **0.002**                                                     648       2.4 (−3.32, 8.12)        0.412       645       −3.08 (−19, 15.9)        0.732
           Visit 3   **647**   **12.4 (6.04, 18.8)**    **0.000**                                                     648       2.33 (−3.9, 8.57)        0.464       645       −15.6 (−30.7, 2.71)      0.092
  MEHHP    Visit 1   646       4.18 (−0.056, 8.41)      0.055                                                         647       −0.128 (−4.24, 3.98)     0.951       644       2.06 (−10.3, 16.1)       0.757
           Visit 3   **646**   **6.15 (1.57, 10.7)**    **0.009**                                                     647       0.538 (−3.93, 5.01)      0.814       644       −8.32 (−20.4, 5.55)      0.229
  MEHP     Visit 1   645       0.557 (−1.61, 2.73)      0.616                                                         646       0.773 (−1.34, 2.89)      0.475       643       3.57 (−3.09, 10.7)       0.303
           Visit 3   **645**   **2.66 (0.247, 5.07)**   **0.032**                                                     646       1.01 (−1.36, 3.38)       0.406       643       −1.72 (−8.82, 5.92)      0.650
  MEOHP    Visit 1   **644**   **5.16 (1.01, 9.32)**    **0.016**                                                     645       0.83 (−3.21, 4.87)       0.687       642       3.45 (−8.84, 17.4)       0.600
           Visit 3   **644**   **6.97 (2.41, 11.5)**    **0.003**                                                     645       1.71 (−2.76, 6.18)       0.454       642       −7.41 (−19.6, 6.58)      0.286
  MEP      Visit 1   642       3.21 (−1.79, 8.21)       0.211                                                         643       1.33 (−3.5, 6.15)        0.591       640       −11.4 (−23.9, 3.2)       0.122
           Visit 3   642       3.22 (−2.07, 8.51)       0.235                                                         643       −1.38 (−6.53, 3.77)      0.601       **640**   **−18 (−30.3, −3.57)**   **0.018**
  MiBP     Visit 1   646       3.63 (−1.22, 8.48)       0.144                                                         647       −1.22 (−5.91, 3.46)      0.609       644       2.91 (−11.2, 19.2)       0.703
           Visit 3   **646**   **5.51 (0.207, 10.8)**   **0.043**                                                     647       0.087 (−5.07, 5.25)      0.974       644       −5.81 (−20, 10.8)        0.472
  MHBP     Visit 1   **435**   **1.79 (0.036, 3.55)**   **0.048**                                                     435       0.127 (−1.59, 1.85)      0.886       436       4.88 (−0.275, 10.3)      0.067
           Visit 3   435       1.18 (−0.741, 3.11)      0.231                                                         435       0.92 (−1.06, 2.9)        0.364       436       4.45 (−1.54, 10.8)       0.152
  MHiBP    Visit 1   **437**   **4.78 (0.552, 9)**      **0.029**                                                     437       −1.56 (−5.7, 2.58)       0.461       438       6.36 (−5.88, 20.2)       0.325
           Visit 3   **437**   **5.03 (0.482, 9.57)**   **0.033**                                                     437       −0.286 (−4.85, 4.28)     0.902       438       −5.04 (−17.1, 8.77)      0.457
  MECPTP   Visit 1   153       3.99 (−3.01, 11)         0.272                                                         153       4.45 (−1.83, 10.7)       0.174       153       5.24 (−14.2, 29.1)       0.627
           Visit 3   153       0.63 (−7.54, 8.8)        0.881                                                         153       −3.14 (−10.6, 4.28)      0.413       153       −2.31 (−23.6, 25)        0.853
  MEHHTP   Visit 1   153       2.96 (−1.2, 7.12)        0.173                                                         153       2.04 (−1.71, 5.79)       0.295       153       2.61 (−9.05, 15.8)       0.678
           Visit 3   153       1.56 (−3.34, 6.46)       0.537                                                         153       −1.27 (−5.75, 3.22)      0.584       153       −3.02 (−16.3, 12.4)      0.686
  MONP     Visit 1   **153**   **3.98 (0.889, 7.08)**   **0.017**                                                     153       1.07 (−1.75, 3.89)       0.461       153       1.49 (−7.24, 11)         0.750
           Visit 3   153       1.58 (−1.73, 4.89)       0.357                                                         153       1.08 (−1.94, 4.1)        0.490       153       −7.72 (−16.3, 1.73)      0.116

                     **Progesterone/E3** [***^a^***](#tblfn10){ref-type="table-fn"}   **T3/T4**                                                                                    
  -------- --------- ---------------------------------------------------------------- --------------------------- ----------- --------- ------------------------ ----------- -- -- --
  MBP      Visit 1   652                                                              −1.68 (−16.2, 15.4)         0.836       649       0.038 (−6.09, 6.16)      0.990             
           Visit 3   652                                                              16.0 (−3.14, 39)            0.109       649       2.56 (−4.09, 9.21)       0.452             
  MBzP     Visit 1   648                                                              −0.193 (−7.25, 7.4)         0.959       644       −0.77 (−3.62, 2.08)      0.597             
           Visit 3   648                                                              7.18 (−1.69, 16.9)          0.118       644       1.51 (−1.68, 4.69)       0.355             
  MCNP     Visit 1   **643**                                                          **−4.37 (−8.09, −0.491)**   **0.029**   640       0.345 (−1.14, 1.83)      0.649             
           Visit 3   643                                                              −3.08 (−7.25, 1.29)         0.167       640       0.483 (−1.09, 2.06)      0.549             
  MCOP     Visit 1   644                                                              −5.61 (−16, 6.1)            0.335       641       1.48 (−2.95, 5.91)       0.513             
           Visit 3   **644**                                                          **−14.0 (−25.3, −1.02)**    **0.037**   641       1.33 (−3.73, 6.39)       0.607             
  MCPP     Visit 1   646                                                              −2.66 (−6.29, 1.11)         0.166       643       0.001 (−1.42, 1.42)      0.999             
           Visit 3   646                                                              −1.80 (−5.87, 2.46)         0.403       643       0.127 (−1.4, 1.65)       0.871             
  MECPP    Visit 1   649                                                              −12.1 (−26.4, 4.94)         0.156       **646**   **6.96 (0.22, 13.7)**    **0.045**         
           Visit 3   649                                                              −2.13 (−19.9, 19.6)         0.834       **646**   **8.9 (1.49, 16.3)**     **0.020**         
  MEHHP    Visit 1   648                                                              −2.59 (−14.4, 10.8)         0.690       645       4.75 (−0.121, 9.62)      0.058             
           Visit 3   648                                                              3.26 (−10.7, 19.4)          0.666       645       4.60 (−0.744, 9.94)      0.094             
  MEHP     Visit 1   647                                                              −1.87 (−8.13, 4.81)         0.575       644       −0.147 (−2.65, 2.36)     0.909             
           Visit 3   647                                                              4.32 (−3.47, 12.7)          0.287       644       0.953 (−1.89, 3.79)      0.512             
  MEOHP    Visit 1   646                                                              −4.30 (−15.7, 8.61)         0.497       643       4.66 (−0.123, 9.44)      0.058             
           Visit 3   646                                                              3.90 (−10.2, 20.2)          0.607       643       4.49 (−0.843, 9.82)      0.101             
  MEP      Visit 1   644                                                              −10.3 (−23, 4.37)           0.161       641       2.03 (−3.74, 7.79)       0.492             
           Visit 3   644                                                              −8.77 (−22.8, 7.83)         0.284       641       4.47 (−1.68, 10.6)       0.157             
  MiBP     Visit 1   648                                                              6.64 (−7.85, 23.4)          0.390       645       4.26 (−1.31, 9.82)       0.136             
           Visit 3   648                                                              6.36 (−9.81, 25.4)          0.465       645       5.41 (−0.73, 11.6)       0.086             
  MHBP     Visit 1   435                                                              −2.88 (−7.56, 2.04)         0.250       435       1.53 (−0.581, 3.65)      0.159             
           Visit 3   435                                                              0.298 (−5.39, 6.32)         0.921       435       0.12 (−2.28, 2.52)       0.922             
  MHiBP    Visit 1   437                                                              −5.93 (−16.5, 5.94)         0.316       **437**   **5.43 (0.365, 10.5)**   **0.038**         
           Visit 3   437                                                              −7.64 (−19.1, 5.43)         0.242       437       4.33 (−1.22, 9.88)       0.130             
  MECPTP   Visit 1   153                                                              −9.01 (−25.7, 11.5)         0.369       153       −1.19 (−8.72, 6.34)      0.759             
           Visit 3   153                                                              0.896 (−21.9, 30.4)         0.946       153       4.73 (−3.92, 13.4)       0.292             
  MEHHTP   Visit 1   153                                                              −5.55 (−16.1, 6.37)         0.354       153       0.221 (−4.28, 4.72)      0.924             
           Visit 3   153                                                              −3.52 (−17.1, 12.3)         0.647       153       3.3 (−1.92, 8.52)        0.225             
  MONP     Visit 1   153                                                              1.1 (−7.61, 10.6)           0.814       153       2.89 (−0.509, 6.28)      0.106             
           Visit 3   153                                                              0.68 (−8.98, 11.4)          0.896       153       0.328 (−3.27, 3.93)      0.859             

All models were adjusted for categorical maternal age, ordinal maternal education, study visit, and specific gravity. *P* values were derived from an interaction term between study visit and log(phthalate). Boldface type indicates a 95% CI.

Note that 405 and 272 women provided samples at visit 1 (median, 18 wk) and visit 3 (median, 26 wk), respectively.

Hormone levels were natural log transformed for all analyses.

An increase in serum testosterone was observed with an IQR increase in MHBP (%*Δ*, 4.71; 95% CI, 0.27, 9.35), but a decrease was seen with an IQR increase in MEP (%*Δ*, −14.5; 95% CI, −24.3, −3.42) over the study period. Study visit had a significant impact on the relationship between testosterone and MCNP (*P* = 0.026) and MCOP (*P* = 0.004) ([Fig. 1](#fig1){ref-type="fig"}). Testosterone concentrations were significantly increased at visit 1 with IQR increases in MCOP (%*Δ*, 16.5; 95% CI, 3.83, 30.7), but were significantly decreased at visit 3 with an IQR increase in MEP (%*Δ*, −18.0; 95% CI, −30.3, −3.57).

![Differences in the effects of phthalate exposures on testosterone concentrations over the study period and at each visit. Note that effect estimates refer to the percent change in serum testosterone levels with an IQR increase in urinary phthalate metabolite concentration, and bars indicate the 95% CI.](js.2019-00010f1){#fig1}

Across the study period, an IQR increase in MCOP was associated with a decrease in SHBG (%*Δ*, −5.66; 95% CI, −11.2, −0.08). There were no significant associations between E3 and any of the phthalate metabolites across the study period or at specific visits. An IQR increase in MCOP was associated with a 9.85% (95% CI, −17.0, −2.03) decrease in progesterone across the study, a relationship being driven by MCOP exposure at visit 1 (%*Δ*, −10.8; 95% CI, −19.4, −1.19). An IQR increase in the terephthalate metabolite MEHHTP was associated with a 13.1% (95% CI, 2.75, 22.3) decrease in progesterone at visit 3 only. A 3.8% (95% CI, 0.725, 6.78) decrease in the ratio of progesterone to E3 was associated with an IQR increase in MCNP over the study duration, whereas a 4.7% (95% CI, 0.491, 8.09) decrease was seen at visit 1. A decrease in the progesterone/E3 ratio was also seen with an IQR increase in MCOP (%*Δ*, −14.0; 95% CI, −25.3, −1.02) at visit 3 only.

C. Thyroid Hormones {#s17}
-------------------

IQR increases in MBP, MCOP, MCPP, and MHBP were significantly associated with 3.39% (95% CI, 0.114, 6.67), 3.03% (95% CI, 0.737, 5.33), 1.31% (95% CI, 0.592, 2.03), and 1.11% (95% CI, −0.004, 2.22) increases in fT4 concentrations over the study period, respectively. At visit 1, IQR increases in MCOP and MCPP were associated with 4.51% (95% CI, 1.73, 7.29) and 1.70% (95% CI, 0.808, 2.59) increases in fT4, respectively, while an IQR increase in MHBP at visit 3 was associated with a 1.75% (95% CI, 0.235, 3.27) increase in fT4. The effect of study visit on the associations between these phthalate metabolites and fT4 was not significant.

IQR increases in MBP, MCOP, and MCPP were associated with 4.61% (95% CI, 0.254, 8.96), 4.02% (95% CI, 1.00, 7.03), and 1.85% (95% CI, 0.909, 2.79) increases in serum T4 concentrations over the study period. Similar relationships existed with MBzP (%*Δ*, 2.58; 95% CI, 0.181, 4.98), MCOP (%*Δ*, 4.66; 95% CI, 0.978, 8.34), and MCPP (%*Δ*, 2.07; 95% CI, 0.896, 3.24) at visit 1, and with MCPP (%*Δ*, 1.59; 95% CI, 0.351, 2.84) at visit 3, but study visit did not have a significant impact on these relationships.

Changes in T3 were significantly associated with IQR increases in MBP (%*Δ*, 6.19; 95% CI, 1.70, 10.7), MBzP (%*Δ*, 2.18; 95% CI, 0.042, 4.32), MCOP (%*Δ*, 5.24; 95% CI, 2.13, 8.35), MCPP (%*Δ*, 1.88; 95% CI, 0.908, 2.86), MECPP (%*Δ*, 10.6; 95% CI, 5.63, 15.6), MEHHP (%*Δ*, 5.05; 95% CI, 1.55, 8.56), MEOHP (%*Δ*, 5.94; 95% CI, 2.45, 9.43), MiBP (%*Δ*, 4.43; 95% CI, 0.212, 8.66), MHBP (%*Δ*, 1.53; 95% CI, 0.031, 3.03), MHiBP (%*Δ*, 4.90; 95% CI, 1.13, 8.67), and MONP (%*Δ*, 2.88; 95% CI, 0.488, 5.27). Increases in T3 concentrations were also found at both study visits with IQR increases in MBP, MCOP, MCPP, MECPP, MEOHP, and MHiBP. Changes in T3 were significant only at visit 1 for IQR increases in MHBP (%*Δ*, 1.79; 95% CI, 0.036, 3.55) and MONP (%*Δ*, 3.98; 95% CI, 0.889, 7.08), and significant only at visit 3 for IQR increases in MEHHP (%*Δ*, 6.15; 95% CI, 1.57, 10.7), MEHP (%*Δ*, 2.66; 95% CI, 0.247, 5.07), and MiBP (%*Δ*, 5.51; 95% CI, 0.207, 10.8). Study visit did not have a significant impact on the relationships between phthalate metabolites and T3.

The T3/T4 ratio increased by 7.79% (95% CI, 2.06, 13.5), 4.68% (95% CI, 0.639, 8.73), 4.58% (95% CI, 0.553, 8.61), and 4.97% (95% CI, 0.498, 9.44) with IQR increases in MECPP, MEHHP, MEOHP, and MHiBP over the study period, respectively. This ratio also increased at visit 1 with IQR increases in MECPP (%*Δ*, 6.96; 95% CI, 0.22, 13.7) and MHiBP (%*Δ*, 5.43; 95% CI, 0.365, 10.5), and at visit 3 with an IQR increase in MECPP (%*Δ*, 8.90; 95% CI, 1.49, 16.3).

3. Discussion {#s18}
=============

In this study, we investigated the longitudinal associations between gestational phthalate biomarker concentrations and maternal serum hormones measured at two time points during pregnancy. Five phthalate metabolites were significantly associated with decreased concentrations of CRH across pregnancy, with most effects being stronger at visit 3 than at visit 1. Total T3 was widely positively associated with phthalate metabolites, and most of those relationships were consistent between study visits. fT4 and total T4 were positively associated with MBP, MCPP, and MCOP, and relationships were also consistent between study visits, although not always significant. Concentrations of the phthalate replacement metabolite MEHHTP was inversely associated with progesterone at visit 3. Associations between phthalates and testosterone were inconsistent, but relationships at visit 1 tended to be positive whereas those at visit 3 tended to be negative. Associations between testosterone and MCNP and MCOP were significantly modified by timing of study visit.

A. Thyroid Hormone Discussion {#s19}
-----------------------------

We previously conducted a case-control study at Brigham and Women's Hospital in Boston among 439 women recruited between 2006 and 2008 to assess longitudinal associations between urinary phthalate concentrations through pregnancy and maternal serum thyroid hormones \[[@B72]\]. That study is consistent with our finding that fT4 concentrations were higher when measured at earlier points in gestation, as well as finding a positive association between MCPP and fT4. Although the current study suggested consistent positive associations between phthalates and T3, the former study found T3 to be positively associated with only MEP, a relationship that was not significant in the current study. In contrast to our current results, the earlier study indicated inverse associations between TSH and several phthalate metabolites, as well as a significant positive relationship between MEHP and T4. Although some aspects of the two studies were similar, they were conducted on distinct populations and at differing recruitment times (2006 to 2008 vs 2012 to 2017) and thus may reflect distinct phthalate usage and exposure patterns.

Romano *et al.* \[[@B73]\] conducted a prospective birth cohort analysis looking at maternal phthalate metabolites and their relationships with thyroid hormones among 202 women in Cincinnati, Ohio. They used urinary phthalate metabolite and maternal serum thyroid hormone measurements at 16 weeks' gestation and found that decreasing T4 concentrations were associated with a 10-fold increase in MEP. This result is not supported by our finding that MEP was not associated with T4 and that several other phthalate metabolites were positively associated with T4. Exposure levels were generally lower than those in the current study, which may be contributing to differing results. Additionally, although the median gestational ages were similar in both studies, measurements ranged from 16 to 20 weeks in our study and 10 to 23 weeks in the study by Romano *et al.*, further suggesting that gestational age may play a critical role in the association between phthalate exposure and maternal thyroid hormones.

We previously conducted a pilot study to analyze thyroid and sex hormones (estradiol, progesterone, SHBG) in relationship to phthalate exposure among a distinct group of 106 pregnant women recruited into PROTECT \[[@B54]\]. The current expanded study is more robust due to a much larger sample size and thus provides more reliable results. In contrast to the present analysis, we previously observed inverse associations between several phthalates and progesterone, SHBG, and fT4. Although not significant in the current study among a much larger sample, many associations were consistent in direction between the two studies.

Several previous studies have been conducted in Taiwan looking at gestational phthalate exposure and maternal thyroid hormones. Among 76 Taiwanese women in their second trimester, it was found that MBP was inversely associated with fT4 and T4 \[[@B74]\], which conflicts with our finding that MBP was positively associated with fT4 and T4. That same group later conducted a similar analysis measuring phthalates and hormones in the first trimester of pregnancy (N = 97) and found that MBP was again inversely associated with T4, but the relationship between MBP and fT4 was no longer significant \[[@B75]\]. Median concentrations of MBP in the earlier study were almost fivefold higher than in our study, whereas MBP concentrations were similar between the later study and ours. Between the two Taiwanese studies in 2011, deliberate contamination with di(2-ethylhexyl)phthalate (DEHP) and di-n-butylphthalate (DBP) as replacements of emulsifiers in many foods and beverages occurred in Taiwan \[[@B76]\]. Stricter regulations put into place following the scandal may be responsible for decreased concentrations of DEHP and DBP metabolite biomarkers found in studies occurring after the scandal. Inverse associations between mBP and fT4 may have been driven by unusually high concentrations of MBP in the earlier Taiwanese population. Each of the Taiwanese studies enrolled \<100 women, limiting their power to detect true associations.

Another study conducted in Taiwan assessed third-trimester phthalate metabolites and maternal serum thyroid hormones \[[@B77]\]. Although they found an inverse association between MBzP and TSH in fetal cord blood, they did not find any associations between phthalates and maternal serum hormones. A pilot study conducted in China reported significant positive associations between MBP and fT4 early in pregnancy (5 to 12 weeks' gestation), but that relationship was null at 13 to 20 weeks \[[@B78]\]. Conversely, a prospective study in China found that first-trimester phthalates measured at ∼10 weeks' gestation were generally inversely associated with fT4 and T4 but positively associated with TSH \[[@B79]\]. Taken together, these studies suggest differential effects of phthalate exposure on maternal thyroid hormones and indicate the importance of gestational age in predicting resulting changes in associations between phthalates and maternal thyroid hormones.

Several studies have sought to determine the mechanism by which phthalates interfere with normal thyroid physiology, but results are inconsistent. Phthalates may exert thyroid-disrupting effects by altering transcription levels of thyroid hormones \[[@B80], [@B81]\] or by exerting thyroid receptor antagonistic activity \[[@B82], [@B83]\]. It has also been suggested that phthalates interfere with biosynthesis of thyroid hormones \[[@B38], [@B39], [@B84]\], possibly by interfering with deiodinase activity that is required for peripheral tissues to convert T4 into the more active T3. In the present study, we observed a significant positive association between MECPP, MEHHP, and MEOHP and both T3 and the T3/T4 ratio. Our results support the possibility that these DEHP metabolites may interfere with normal levels of conversion of T4 to T3 by peripheral tissues, but more research including measurement of deiodinase activity needs to be conducted to better understand these relationships. Thyroid hormones play critical roles during pregnancy, including direct action on the placenta to promote growth and proliferation \[[@B85]\], promotion of proper fetal growth and neurodevelopment \[[@B86]\], and placental transfer of maternal thyroid hormones upon which the fetus is totally dependent in the first trimester \[[@B87]\]. It has previously been shown that elevated levels of T3 are significantly associated with risk of preterm birth \[[@B88]\], suggesting that exposure to phthalates may increase risk for preterm birth via elevation of maternal T3.

B. CRH and Reproductive Hormone Discussion {#s20}
------------------------------------------

Human studies of reproductive hormones have been more limited. Two previous studies have been conducted, both by the same group, looking at the relationship between urinary phthalate metabolite concentrations and maternal serum testosterone during pregnancy \[[@B89], [@B90]\]. The first study took biomarker measurements late in pregnancy (98% of women were \>20 weeks' gestation), whereas the second study took biomarker measurements early in pregnancy (99.5% of women were \<20 weeks' gestation). Inverse associations with MBP and the sum of DEHP metabolites, as well as positive associations with MEP, were found with testosterone during late pregnancy but not early pregnancy. Those results are not consistent with our finding that MBP was not significantly associated with testosterone at either visit during pregnancy, or that MEP was inversely associated with testosterone later in pregnancy. Distributions of phthalate metabolite concentrations differed between the three studies, which may be driving differences in results. Additionally, the range of gestational ages used in the two previous studies may be too wide to detect the true effects of phthalates on testosterone at different points during pregnancy.

To our knowledge, no previous epidemiological studies have been conducted to evaluate the association between phthalate exposure and CRH. An *in vitro* study utilizing primary cytotrophoblast cells from term human placentas exposed cells to MEHP and quantified the subsequent protein and mRNA expression levels of CRH. They found that MEHP treatment significantly increased both CRH protein and mRNA levels. They also found that MEHP treatment significantly increased cytoplasmic-to-nuclear translocation of the RelB/p52 heterodimer, a process in the noncanonical nuclear factor *κ*B (NF-kB) pathway that causes upregulation of CRH expression in the human placenta. Additionally, knockdown of NIK, a critical component of the noncanonical NF-*κ*B pathway that induces processing of p100 into active p52 so it can heterodimerize with RelB, was found to diminish the effect of mEHP treatment on upregulation of CRH, suggesting that the effects of MEHP exposure on CRH expression is dependent on NIK activity \[[@B91]\]. The NF-*κ*B signaling pathway has been implicated as a strong regulator in the process of initiating labor and thus provides clues as to how phthalate exposure may influence CRH concentrations to affect timing of labor \[[@B92]\]. These results conflict with our finding that MCNP, MCPP, MECPP, MEHHP, and MEOHP were significantly inversely associated with maternal serum CRH concentrations through pregnancy, whereas MEHP was not significantly associated with CRH. Previous research suggests that phthalates possess proinflammatory properties \[[@B93], [@B94]\], and CRH is known to be a potent proinflammatory factor. Phthalate exposure may result in increased concentrations of other proinflammatory factors, thus increasing maternal systemic inflammation, which may lead to a decrease in CRH concentrations to attempt to combat increased inflammation. CRH concentrations are relatively low late in the second trimester and begin to exponentially increase at ∼20 weeks and peak at the onset of labor. Responses to higher phthalate exposures may have differential impacts on CRH concentrations beyond 26 weeks' gestation, as more pro-labor events begin to occur, indicating the importance of studying the associations between phthalates and CRH at both early and late stages of pregnancy. Importantly, also note that concentrations of CRH binding proteins are particularly high during pregnancy \[[@B95]\], and our assay measured total (both bound and unbound forms) of CRH, thus reported concentrations are not necessarily indicative of bioactive concentrations.

Progesterone plays critical roles throughout pregnancy, including suppression of the maternal immune system so that the fetus is not rejected, promotion of various inflammatory events at the end of pregnancy to induce labor, and helping to hold off contractions and inflammatory events until the end of the pregnancy \[[@B96]\]. Our results showed that exposure to MEHHTP, a metabolite of the terephthalate DEHTP, was associated with a significant decrease in maternal progesterone concentrations later in pregnancy. Levels of terephthalate metabolites we present in the present study are higher than those found among a convenience sample of US women prior to 2016 (median of 1.1 vs 2.9 ng/mL) in a recent study published by the Centers for Disease Control and Prevention \[[@B53]\]. As phthalate replacement chemicals are used more frequently in the manufacturing of consumer products, it will be increasingly important to understand the potential health threats they pose, particularly among at-risk populations such as pregnant women. To our knowledge, this is the first epidemiological study to date to look at metabolites of terephthalates, and our results further indicate the need to consider these chemicals in future human health studies.

Our study has several limitations. We did not have data on maternal serum concentrations of iodine or thyroid peroxidase antibodies, both of which can impact measured concentrations of serum thyroid hormones \[[@B5], [@B74]\]. Not measuring these factors limits our ability to hypothesize mechanisms of phthalate action on thyroid hormones and could have introduced bias to our study. Measuring phthalates and hormones at two time points during pregnancy that align with periods of rapid fetal growth rather than trimesters is an improvement on most published research on this topic; however, two time points may not be sufficient to detect different effects of phthalates on hormones at different times through gestation. Phthalates have also been shown to have high variability within individuals, suggesting that single phthalate measurements are not typically indicative of long-term exposure. However, exposure to certain phthalates may come from sources that are consumed habitually, making some of our measurements more reliable. Finally, we carried out many comparisons and thus some of our significant results may have been found by chance. Our study also has numerous strengths. Despite the risk of excess type I error from carrying out many comparisons, we were able to explore relationships that have not been well studied, particularly those between reproductive hormones and emerging phthalate replacement chemical metabolites. We present one of few studies to longitudinally assess phthalate associations with maternal hormones during pregnancy, and our sample size was greater than that of most other studies. We explore relationships between phthalates and CRH in an epidemiological study, and we also explore metabolites of DEHTP, a terephthalate currently being used as a replacement for DEHP, for associations with human health measures. Our repeated measures analysis also allows us to control for intraindividual variability of measured biomarkers, enhancing our statistical power. Lastly, biomarker measurements at two different points during gestation allows for examination of possible windows of susceptibility to phthalate exposure during pregnancy.

Overall, our results suggest that gestational phthalate exposures are associated with maternal serum concentrations of CRH, testosterone, and thyroid hormones through pregnancy, and that the direction of these relationships is not consistent. Visit-specific results indicate that timing of exposure during pregnancy has a significant impact on associations with maternal hormone levels. These results also suggest that phthalate replacement chemicals may disrupt maternal reproductive hormones during pregnancy. Future studies utilizing more frequent measurements through pregnancy and larger sample sizes for phthalate substitutes are needed to support our findings. People are rarely exposed to individual phthalate chemicals, and thus studying exposures to mixtures of phthalates will be an important future step to gain a potentially fuller understanding of associations between environmental exposures and hormone levels. Future studies should also aim to assess how the impact of phthalate exposure on maternal hormones may mediate birth outcomes and child development.
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